tbuckley/cabot-search huggingface dataset:
Late Night Encounter at the Children’s Hospital’s ICU
Authors: William Varner
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of Major Adverse Cardiovascular Events Following Nicotinamide Exposure
Authors: Lee Wheless, Ranya Guennoun, Basia Michalski-McNeely, Katlyn M. Gonzalez, Rachel Weiss, Siwei Zhang, Lydia Yao, Chris Madden, Hua-Chang Chen, Jefferson L. Triozzi, Ran Tao, Otis Wilson, Quinn S. Wells, Adriana Hung, Kristin Bibee, Rebecca I. Hartman, Yaomin Xu, Sumitra Muralidhar, Jennifer Moser, Jennifer E Deen, Philip S Tsao, J. Michael Gaziano, Elizabeth Hauser, Amy Kilbourne, Michael Matheny, Dave Oslin, Deepak Voora, Jessica V Brewer, Mary T Brophy, Kelly Cho, Lori Churby, Scott L DuVall, Saiju Pyarajan, Robert Ringer, Luis E Selva, Shahpoor (Alex) Shayan, Brady Stephens, Stacey B Whitbourne, Themistocles L Assimes, Adriana Hung, Henry Kranzler
Journal: JAMA Dermatology (2025)

Nicotinamide metabolites have recently been implicated in increased risk of major cardiovascular events (MACE). Supportive data about clinical risk of MACE for nicotinamide users is lacking. To determine whether nicotinamide use results in an increase of MACE. This study used retrospective electronic health record data of 2 patient cohorts, the Vanderbilt University Medical Center (VUMC) and Million Veteran Program (MVP). The risk of MACE in patients exposed to nicotinamide was compared with the risk of MACE in unexposed patients. In the VUMC cohort, patients were either exposed to nicotinamide based on keyword entry for nicotinamide or niacinamide and manual review of medical records or were unexposed but had documented recommendation for use. In the MVP cohort, those exposed to nicotinamide were matched via propensity scores to those who were not exposed. Data were collected from January 1989 to February 2024, and data were analyzed from March to December 2024. The primary exposure for the VUMC cohort was a confirmed exposure to nicotinamide on medical record review. The primary exposure for the MVP cohort was medication entry for nicotinamide or niacinamide. The primary outcome was development of MACE based on a validated phenotype. Of 13 108 included patients, 11 926 (91.0%) were male, and the mean (SD) age was 66.8 (11.5) years. In the VUMC cohort, 1228 patients were exposed to nicotinamide and 253 were unexposed; in the MVP cohort, 4063 were exposed and 7564 were not. A total of 5291 had exposure to nicotinamide. Neither cohort had significant differences in mean age, sex, race, or ethnicity between the nicotinamide exposed and unexposed groups. There was no difference in the cumulative incidence of MACE after nicotinamide exposure in either the VUMC cohort or MVP cohorts. In adjusted cause-specific models stratified by history of prior MACE, there was no significant association between nicotinamide exposure and the primary outcome of MACE in either the VUMC cohort (no prior MACE: hazard ratio [HR], 2.02; 95% CI, 0.81-5.05; prior MACE: HR, 0.46; 95% CI, 0.22-0.95) or MVP cohort (no prior MACE: HR, 1.07; 95% CI, 0.75-1.17; prior MACE: HR, 1.04; 95% CI, 0.53-2.06). In this retrospective cohort study of 13 108 adults from 2 different patient populations, there was no increased risk of MACE in patients with nicotinamide exposure.
Indocyanine Green for Vagus Nerve–Preserving Gastrectomy
Authors: Song Liu, Meng Wang, Wenxian Guan
Journal: JAMA Surgery (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Racing Against Time in Thoracotomy for Traumatic Cardiac Arrest
Authors: Christine M. Leeper, Josh B. Brown, Brian S. Zuckerbraun
Journal: JAMA Surgery (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis
Authors: April W. Armstrong, Kathryn Lee, Danielle Yee, Michael Woodbury, Melissa Zundell, Caterina Zagona-Prizio, Jenna Yousif, Carly Grant, Ali Shields, Peichi Chou, Kristina Callis Duffin, Alice B. Gottlieb, Joseph F. Merola, Lourdes Perez-Chada
Journal: JAMA Dermatology (2025)

A critical need exists for developing a validated dermatologic-specific treatment satisfaction instrument. To evaluate the structural validity, internal consistency, construct validity, and test-retest reliability of the 7-item dermatology-specific treatment satisfaction (DermSat-7) instrument in patients with psoriasis. This survey study was conducted from July 2020 to April 2023 in dermatology outpatient clinics at the University of Southern California, Brigham and Women's Hospital, and Mount Sinai Union Square and included adults (aged ≥18 years) with psoriasis who were fluent in English. On day 1, the clinician at the study sites assessed psoriasis disease severity in person using the Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Physician Global Assessment (PGA). On day 1, study participants completed the DermSat-7, the generic 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), and the Dermatology Life Quality Index (DLQI). They also answered demographic questions and reported their own disease severity using the Patient Global Assessment (PtGA). On day 14 (±2 days), the patient then completed the DermSat-7 and PtGA a second time. The DermSat-7 is a 7-item self-administered instrument with a recall period of 14 days that assesses patient satisfaction with their treatments across various inflammatory dermatology diseases, including psoriasis. Construct validity, structural validity, internal consistency, and test-retest reliability of DermSat-7 were assessed as defined by the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) taxonomy and reported following the COSMIN reporting guideline for studies on measurement properties. The analysis included 142 patients with psoriasis (mean [SD] age, 51.1 [15.5] years; 77 males [54.2%]). Exploratory factor analysis and confirmatory factor analysis supported the unidimensionality of the DermSat-7 domains. The internal consistency of the effectiveness and convenience domains was high with a Cronbach α of 0.88 and 0.81, respectively. Regarding construct validity, differences between groups based on PASI/PGA scores were aligned with preexisting hypotheses, and the correlations between DermSat-7 and TSQM-9 subscores were strong to very strong (ρ = 0.75 for effectiveness; ρ = 0.66 for convenience; and ρ = 0.70 for overall satisfaction; all P < .001). Intraclass correlation was 0.85, indicating high test-retest reliability. This survey study found that the DermSat-7 may be a valid and reliable instrument for measuring treatment satisfaction in patients with psoriasis.
Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering
Authors: Nicholas A. Marston, Frederick K. Kamanu, Giorgio E. M. Melloni, Gavin Schnitzler, Aaron Hakim, Rosa X. Ma, Helen Kang, Daniel I. Chasman, Robert P. Giugliano, Patrick T. Ellinor, Paul M. Ridker, Jesse M. Engreitz, Marc S. Sabatine, Christian T. Ruff, Rajat M. Gupta
Journal: Nature Medicine (2025)
Effects of clinical donor characteristics on the success of faecal microbiota transplantation for patients in Denmark with Clostridioides difficile infection: a single-centre, prospective cohort study
Authors: Anne Karmisholt Grosen, Susan Mikkelsen, Lotte Aas Hindhede, Sara Ellegaard Paaske, Simon Mark Dahl Baunwall, Mette Mejlby Hansen, Jens Frederik Dahlerup, Martin Steen Mortensen, Tine Rask Licht, Jens Kjærgaard Boldsen, Lise Tornvig Erikstrup, Christian Lodberg Hvas, Christian Erikstrup
Journal: The Lancet Microbe (2025)

Faecal microbiota transplantation (FMT) is an effective treatment for patients with recurrent Clostridioides difficile infection, but donor selection can influence its clinical success. We aimed to investigate the effect of clinical donor characteristics on FMT outcomes in patients with C difficile infection. In this single-centre, prospective cohort study, we included all donors who fulfilled the national criteria for faeces donation and delivered donations to the Centre for Faecal Microbiota Transplantation, Aarhus University Hospital, Denmark, between May 2, 2016, and Oct 31, 2023, and corresponding recipients treated with one-dose FMT for primary or recurrent C difficile infection. In mixed-effects models, we evaluated the effect of donor sex, age, BMI, smoking status, donation stool consistency, total donation weight, antibiotic use, Helicobacter pylori carriage, birth mode, donor-recipient sex concordance, and the alpha diversity of faeces donations on FMT outcomes in recipients. The primary outcome was the resolution of diarrhoea associated with C difficile infection in patients 8 weeks after FMT. Among 145 blood donors who also donated faeces, 115 (79·3%) were men and 30 (20·7%) were women. 90 (62·1%) provided faeces for 1351 evaluable FMTs in 952 patients with C difficile infection. 1037 (76·8%) FMTs were administered through oral capsules, 151 (11·2%) via colonoscopy, and 163 FMTs (12·1%) via nasojejunal tube. Antibiotic use 3-12 months before donation decreased the effectiveness of FMT (odds ratio 0·55 [95% CI 0·33-0·91]; p=0·019). Compared with donations with a Bristol Stool Form Scale (BSFS) score of 3, donations with a score of 4 (odds ratio 1·38 [95% CI 1·04-1·83]; p=0·024) and 5 or above (2·89 [1·33-6·26]; p=0·0072) showed improved FMT effectiveness. Donor sex, BMI, smoking status, H pylori carriage, birth mode, total donation weight, and donor-recipient sex concordance did not affect FMT outcomes. Expanding current donor selection criteria to avoid antibiotic use in the 12 months preceding donation and including donations with a BSFS score of 5 might improve FMT outcomes for patients with C difficile infection. Our findings call for the revision of current clinical donor screening practices, and future studies could further optimise the criteria for selecting optimal faeces donors. Innovation Fund Denmark.
A rapid facility-level assessment of oxygen systems in 39 low-income and middle-income countries: a cross-sectional study
Authors: Nadir Ijaz, Tamsin Lee, Nicholas Furtado, Emilie Macher, Zipporah Muitheri, Benjamin J Park, David Lowrance
Journal: The Lancet Global Health (2025)

Unequal access to medical oxygen is a key driver of global inequities in morbidity and mortality. We aimed to describe reliable oxygen availability (ie, whether availability is uninterrupted) and functional availability (ie, whether oxygen system components are in working order) in 39 low-income and middle-income countries and to compare across WHO subregions. We report cross-sectional survey data from primary, secondary, and tertiary level health facilities across six WHO subregions. Facilities were selected via purposive and stratified random sampling. Data collectors visited facilities from September 2022, to February 2023, to administer a standardised questionnaire to facility leadership. All approached facilities responded. Questions assessed reliable oxygen availability over the preceding 3 months and the functional availability of system components: oxygen sources (ie, cylinders, concentrators, plants, and liquid oxygen), distribution systems (ie, piping, cylinder transport, and respiratory tubing), delivery devices (ie, nasal interfaces, face masks, and advanced modalities), monitoring devices (ie, pulse oximeters and multiparameter monitors), and quality assurance (ie, oxygen concentration control and maintenance schedule). We report descriptive statistics and compare across subregions using χ2 and Fisher exact tests. Of 2884 surveyed facilities, 304 (24·5%) of 1241 primary facilities, 558 (52·4%) of 1064 secondary facilities, and 387 (66·8%) of 579 tertiary facilities reported reliable oxygen availability. Facilities across levels and subregions lacked system components, with statistically significant (p<0·05) differences in functional availability of all oxygen system components across subregions at all levels. For example, functional availability of cylinders ranged from 56·7% to 100·0%, piping from 7·5% to 94·6%, nasal cannulae from 56·3% to 96·4%, and pulse oximeters ranged from 47·8% to 96·4%, depending on level and subregion. Reliable oxygen availability was low across facility levels and subregions. There were significant disparities in the functional availability of oxygen system components across subregions, with important implications for global health equity and financing. The Global Fund to Fight AIDS, Tuberculosis, and Malaria; the Yale National Clinician Scholars Program; the US National Center for Advancing Translational Sciences; the US National Heart, Lung, and Blood Institute; and the Yale Institute for Global Health. For the French translation of the abstract see Supplementary Materials section.
Role of non-human primate models in accelerating research and developing countermeasures against Zika virus infection
Authors: Amanda Li, Lark L Coffey, Emma L Mohr, Jessica Raper, Ann Chahroudi, Karla K Ausderau, Matthew T Aliota, Thomas C Friedrich, Ann M Mitzey, Michelle R Koenig, Thaddeus G Golos, Hannah K Jaeger, Victoria H J Roberts, Jamie O Lo, Jessica L Smith, Alec J Hirsch, Daniel N Streblow, Christina M Newman, David H O'Connor, Eve M Lackritz, Koen K A Van Rompay, Kristina M Adams Waldorf
Journal: The Lancet Microbe (2025)

Zika virus, a mosquito-transmitted orthoflavivirus, has become a pathogen of global health concern ever since the virus caused an epidemic in Brazil in 2015 associated with approximately 700 000 laboratory-confirmed cases of congenital microcephaly. The subsequent spread of the epidemic in 2016 resulted in a wide spectrum of congenital neurological, ophthalmological, and developmental abnormalities across the Americas, Africa, and Asia. In this context, non-human primate models have become essential tools for Zika virus research to understand the pathogenesis of congenital brain injury and perinatal complications and for developing and testing medical countermeasures such as vaccines, diagnostics, and therapeutics. Fetal brain injury has been observed across various non-human primate species and is influenced by factors such as the Zika virus strain, gestational age at inoculation, and inoculation dose and route. Miscarriages are also seen as common outcomes of first trimester Zika virus infections. This Series paper reviews the diverse non-human primate models currently used for Zika virus research to mitigate the public health effects of future Zika virus epidemics.
Zika virus: advancing a priority research agenda for preparedness and response
Authors: Eve M Lackritz, Lee-Ching Ng, Ernesto T A Marques, Ingrid B Rabe, Nigel Bourne, J Erin Staples, Jairo A Méndez-Rico, Eva Harris, Aaron C Brault, Albert I Ko, David W C Beasley, Tabitha Leighton, Annelies Wilder-Smith, Julia T Ostrowsky, Angela J Mehr, Angela K Ulrich, Raman Velayudhan, Josephine P Golding, Petra C Fay, Ana Cehovin, Nicolina M Moua, Kristine A Moore, Michael T Osterholm, Alan D T Barrett
Journal: The Lancet Infectious Diseases (2025)
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
Authors: Julia T Ostrowsky, Leah C Katzelnick, Nigel Bourne, Alan D T Barrett, Stephen J Thomas, Michael S Diamond, David W C Beasley, Eva Harris, Annelies Wilder-Smith, Tabitha Leighton, Angela J Mehr, Nicolina M Moua, Angela K Ulrich, Ana Cehovin, Petra C Fay, Josephine P Golding, Kristine A Moore, Michael T Osterholm, Eve M Lackritz
Journal: The Lancet Infectious Diseases (2025)
Specimen and data sharing to advance research and development on Zika virus
Authors: Rosanna W Peeling, Noah T Fongwen, Maria G Guzman, Jairo Andres Méndez-Rico, Michael Selorm Avumegah, Thomas Jaenisch, Eve M Lackritz
Journal: The Lancet Microbe (2025)

For diseases with epidemic potential, specimen and data sharing is crucial for sustained research and development of medical countermeasures such as diagnostics, therapeutics, and vaccines. In the case of Zika virus, although a global framework for specimen and data sharing to advance research and development is highly desirable, challenges related to legal, ethical, and intellectual property issues persist. Since the 2015-16 Zika virus outbreak, regional laboratory networks and research partnerships have made some progress in specimen and data sharing among some Zika virus-endemic countries. Pragmatic steps such as securing funds for augmenting laboratory capacity, building biobanks within public health laboratory infrastructures in low-income and middle-income countries, clearly defining the specimens and data that need to be collected, developing standardised protocols, harmonising data system interoperability to facilitate sharing, and defining mechanisms for benefit sharing will pave the way for timely development and deployment of medical countermeasures in public health emergencies.
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis
Authors: Edward Christopher Dee, Mathieu Laversanne, Nirmala Bhoo-Pathy, Frances Dominique V Ho, Erin Jay G Feliciano, Michelle Ann B Eala, Frederic Ivan L Ting, Ophira Ginsburg, Fabio Ynoe Moraes, Bishal Gyawali, Scarlett Lin Gomez, Kenrick Ng, James Fan Wu, Urvish Jain, Bhav Jain, Rod Carlo Columbres, Tomohiro Matsuda, Suleeporn Sangrajrang, Evlina Suzanna Sinuraya, Tung Duc Bui, Wenqiang Wei, Young-Joo Won, Ling Li Foo, Mei Chuan Annie Ling, Les Mery, Isabelle Soerjomataram, Freddie Bray
Journal: The Lancet Oncology (2025)
Engineering Long-Lived Charge Separation States Boosts Type-I ROS Generation for Efficient Cancer Therapy
Authors: Zhongyan Hu, Wenjing Liu, Jianyu Zhang, Xiaoyu Guo, Huaquan Fang, Junjun Ni, Jacky W Y Lam, Ryan T K Kwok, Feng Xu, Guorui Jin, Ben Zhong Tang
Journal: Biomaterials (2025)
Endoscopic ultrasound-guided tissue sampling: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review
Authors: Antonio Facciorusso, Marianna Arvanitakis, Stefano Francesco Crinò, Carlo Fabbri, Adele Fornelli, John Leeds, Livia Archibugi, Silvia Carrara, Jahnvi Dhar, Paraskevas Gkolfakis, Beate Haugk, Julio Iglesias Garcia, Bertrand Napoleon, Ioannis S. Papanikolaou, Andrada Seicean, Pauline M. C. Stassen, Peter Vilmann, Tony C. Tham, Lorenzo Fuccio
Journal: Endoscopy (2025)

Abstract This Technical and Technology Review from the European Society of Gastrointestinal Endoscopy (ESGE) represents an update of the previous document on the technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology, including the available types of needle, technical aspects of tissue sampling, new devices, and specimen handling and processing. Among the most important new recommendations are: ESGE recommends end-cutting fine-needle biopsy (FNB) needles over reverse-bevel FNB or fine-needle aspiration (FNA) needles for tissue sampling of solid pancreatic lesions; FNA may still have a role when rapid on-site evaluation (ROSE) is available. ESGE recommends EUS-FNB or mucosal incision-assisted biopsy (MIAB) equally for tissue sampling of subepithelial lesions ≥20 mm in size. MIAB could represent the first choice for smaller lesions (&lt;20 mm) if proper expertise is available. ESGE does not recommend the use of antibiotic prophylaxis before EUS-guided tissue sampling of solid masses and EUS-FNA of pancreatic cystic lesions.
Synergistic microglial modulation by laminarin-based platinum nanozymes for potential intracerebral hemorrhage therapy
Authors: Xiumei Guo, Qionghua Zheng, Wen Gao, Yinfeng Xiao, Liyong Shi, Fenglin Lin, Yu Xiong, Yin Zhang, Qiuxia Xu, Lingxing Wang, Shaobin He, Feng Zheng
Journal: Biomaterials (2025)
Building capacity to address equity in sexual wellbeing among transgender and gender expansive communities in Philadelphia, United States
Authors: Louis Listerud, Blake Kosciow, Ari Kirkman, Alana Richards, Ayden Scheim, Elena Cyrus, Dalmacio D. Flores, Falon Seibert-Burns, Naiymah A. Sanchez, Abigail Kopf, Ahmea Branch, Robert K. Graves, Lee Carson, Steven Meanley
Journal: International Journal of Transgender Health (2025)